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Abstract
Background
Polyunsaturated n-3 and n-6 polyunsaturated fatty acids (PUFA) are precursors of biologi-
cally active metabolites that affect blood pressure (BP) regulation. This study investigated
the association of n-3 and n-6 PUFA and BP in children and adolescents.
Methods
In a subsample of 1267 children aged 2–9 years at baseline of the European IDEFICS
(Identification and prevention of dietary- and lifestyle-induced health effects in children and
infants) cohort whole blood fatty acids were measured by a validated gas chromatographic
method. Systolic and diastolic BP was measured at baseline and after two and six years.
Mixed-effects models were used to assess the associations between fatty acids at baseline
and BP z-scores over time adjusting for relevant covariables. Models were further esti-
mated stratified by sex and weight status.
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Results
The baseline level of arachidonic acid was positively associated with subsequent systolic
BP (β = 0.08, P = 0.002) and diastolic BP (β = 0.07, P<0.001). In thin/normal weight chil-
dren, baseline alpha-linolenic (β = -1.13, P = 0.003) and eicosapentaenoic acid (β = -0.85,
P = 0.003) levels were inversely related to baseline and also to subsequent systolic BP and
alpha-linolenic acid to subsequent diastolic BP. In overweight/obese children, baseline
eicosapentaenoic acid level was positively associated with baseline diastolic BP (β = 0.54,
P = 0.005).
Conclusions
Low blood arachidonic acid levels in the whole sample and high n-3 PUFA levels in thin/nor-
mal weight children are associated with lower and therefore healthier BP. The beneficial
effects of high n-3 PUFA on BP were not observed in overweight/obese children, suggest-
ing that they may have been overlaid by the unfavorable effects of excess weight.
Introduction
Hypertension is a major public health issue in industrialized countries. Given the high preva-
lence of overweight and obesity in all age groups, already children are affected by elevated
blood pressure (BP) [1–4]. Further, elevated childhoodBP has been shown to predict elevated
BP in adolescence and adulthood [5–7] and other adulthood cardiovascular diseases [8–10].
Serum and erythrocyte fatty acids (FA) have been suggested to be associated with BP in adults
[11–13] although not all studies confirmed this association [14].
In particular, polyunsaturated fatty acids (PUFA) and their metabolites, the long-chain
PUFA (LC PUFA) such as eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid
(DHA, 22:6n-3) of the n-3 series and arachidonic acid (ARA, 20:4n-6) of the n-6 series have
been linked to BP [11, 12, 14]. As precursors for the production of prostaglandins and throm-
boxanes with effects on vasodilation and platelet aggregation LC PUFA can affect BP [15].
Additionally, ARA and EPA are substrates for the cytochrome P450 (CYP450) catalyzed bio-
synthesis of metabolites of which the ARAmetabolite 20-hydroxyeicosatetraenoic acid
(20-HETE) has been shown to act as a vasoconstrictor. In contrast, epoxides of ARA like epox-
yeicosatrienoic acids (EETs) and of n-3 LC PUFA like epoxyeicosatetraenoic acids seem to
exert BP lowering effects, e.g. by increasing nitric oxide production and vasodilation [16, 17].
Beneficial effects of n-3 LC PUFA on BP have also been attributed to their role as competitors
of n-6 LC PUFA in the biosynthesis of eicosanoids and lipid mediators including those cata-
lyzed by CYP450 [18]. Additionally, 20-HETE and EETs are involved in renal tubular and vas-
cular function that may affect BP [19–21].
Intervention studies with fish oil supplements or n-3 rich fatty fish showed a small blood
pressure lowering effect [22]. Also a meta-analysis of randomized controlled trials with EPA
and DHA supplementation concluded that n-3 LC PUFA lowers systolic BP (SBP) and in high
doses also diastolic BP (DBP) [23]. However, data from observational studies and from the lim-
ited number of intervention studies in children are less consistent [18]. Three studies reported
positive associations between childhoodn-3 LC PUFA and BP. In Danish children, cross-sec-
tional data indicated whole blood EPA to be positively associated with DBP in boys but not in
girls [24] while in Danish adolescents DHA was positively associated with SBP [25]. In a
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Finnish cohort, the sum of serum cholesterylester n-3 PUFA in childhoodwas positively asso-
ciated with BP in adulthood after 27 years in males but not in females [26]. Against the back-
ground of the presumed biologicalmechanisms and results of intervention studies in adults,
the reported positive associations of n-3 PUFA and BP were unexpected.Therefore, this study
investigates the cross-sectional and prospective associations betweenwhole blood n-3 and n-6
PUFA and BP in a large cohort of European children.
Methods
Study group
In the IDEFICS (Identification and prevention of dietary- and lifestyle-inducedhealth effects
in children and infants) baseline survey (T0) in 2007/2008, a population-based sample of 16
228 children aged 2 to 9.9 years from eight European countries (Belgium,Cyprus, Estonia, Ger-
many, Hungary, Italy, Spain, Sweden) was examined. Follow-up examinations were conducted
two (T1) and six (T3, I.Family study) years later; the study design has been described in detail
elsewhere [27, 28]. In brief, the IDEFICS/I.Family study comprises one of the largest prospec-
tive European child cohorts. The main focus of the IDEFICS study was to investigate diet- and
lifestyle related disorders in young children with a focus on overweight and obesity. A further
follow-up of the health status including 7105 children of the original IDEFICS cohort was per-
formed in the I.Family study to explore the determinants of dietary and other lifestyle behav-
iors in these children and adolescents as they have grown older. A large set of anthropometric
and clinical examinations was conducted and biosamples were taken as well as several ques-
tionnaires and interviewswere collected. Lifestyle behaviors like dietary intake, physical activity
and screen time of young children up to the age of 11 years were reported by parents whereas
this information was self-reported by adolescents. Parents reported their own educational level
and lifestyle behaviors like smoking in self-completion questionnaires. In a face-to-face inter-
view the health conditions of the participating child and the family history of diseases were col-
lected by trained interviewers.
Since in IDEFICS community- and setting-oriented intervention programs were imple-
mented, in each country two mutually comparable areas have been allocated to either serve as
intervention or control region [29].
Parents gave written informed consent for themselves and for their participating children.
Children aged 12 years and over also gave written informed consent while small children gave
oral consent prior to the start of the examinations. The participating centers in each country
obtained ethical approval by the competent Institutional ReviewBoards prior to starting the
study. These were the following ethics committees: Ethics Committee, University Hospital,
Gent, Belgium;Cyprus National Bioethics Committee, Nicosia, Cyprus; Tallinn Medical
Research Ethics Committee, Tallinn, Estonia; Ethics Committee of the University of Bremen,
Bremen, Germany; EgészségügyiTudományos Tanács, Pécs, Hungary; Azienda Sanitaria
LocaleAvellino Comitato Etico, Avellino, Italy; Regionala Etikprövningsnämnden i Göteborg,
Gothenburg, Sweden; Comité Ético de Investigación Clínica de Aragón, Zaragoza, Spain. The
examinations were conducted by trained field work teams. The authors of this manuscript had
no contact to the participants.
This study is based on a subsample of IDEFICS T0 participants with an oversampling of
overweight and obese children [27]. FA profiles were analyzed in 2600 children of which 10
children were excluded because of blood drawing in a non-fasting state. Furthermore, only
children with at least one follow-up measurement were included such that additional 1297 chil-
dren had to be excluded due to missing BP, missing follow-up or missing covariate data.
Because the remaining sample of children from Belgium and Cyprus consisted of only 15 and
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11 children, respectively, these were not considered in the final analysis resulting in an analysis
sample of 1267 children (Fig 1). The age range of the children was 2–9 years at T0, 4–11 years
at T1 and 9–16 years at T3, respectively.
Exposures
Bloodwas obtained by collecting a drop of blood from a fingertip or by venipuncture which
was applied directly to a test strip prepared with butylated hydroxytoluene (BHT). FA in whole
bloodwere separated and determined by gas-liquid chromatography after direct derivatisation
to their methyl esters without prior extraction of total lipids from the samples in a central labo-
ratory as previously described [30, 31]. This simple and rapid analysis method was validated by
several laboratories [31–33]. Whole blood includes FA from all lipid classes and is representa-
tive for the total FA pool [32]. In the present analysis we used FA values of the n-3 PUFA
alpha-linolenic acid (ALA, 18:3n-3), eicosapentaenoic acid and docosahexaenoic acid and the
n-6 PUFA linoleic acid (LA, 18:2n-6), gamma-linolenic acid (GLA, 18:3n-6), dihomo-gamma-
linolenic acid (DGLA, 20:3n-6) and arachidonic acid. FA are expressed as weight percentage of
all FA detected (% wt/wt).
Outcomes
SBP and DBP was measured at the right arm with a cuff of appropriate size for arm circumfer-
ence after at least 5 minutes of rest in seated position according to a standardized protocol with
Fig 1. Flow chart of the inclusion and exclusion of IDEFICS/I.Family participants.
doi:10.1371/journal.pone.0165981.g001
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an automated oscillometricdevice (Welch Allyn, Inc., 4200B-E2, Skaneateles Falls, NY, USA)
[34]. Two recordings were taken, with a 2-min interval between each, plus a third measurement
in case of a>5% difference between the first two readings. The mean value of the two measure-
ments with the smallest difference was used as outcome measure. If the first and secondmea-
surement deviated by>5% and no third measurement value was obtained BP was set to
missing. For SBP, DBP and BP classification to normal BP, pre-hypertension and hypertension,
age, sex and height specific reference values from the US Department of Health and Human
Services,National Institutes of Health (NIH, 2005) [35] were applied. SBP and DBP were fur-
ther transformed to age-, sex- and height-specific z-scores according to the NIH references and
were used as outcome variables in the subsequent analysis.
Anthropometric data
Height of the children was measured to the nearest 0.1 cm with a calibrated stadiometer (Seca
225/213 stadiometer, Birmingham, UK). Body weight was assessed in fasting state in light
underwear on a calibrated scale accurate to 0.1 kg (adapted Tanita BC 420 MA for children6
years, BC 418 MA for children>6 years, Tanita Europe GmbH, Sindelfingen, Germany). BMI
was calculated as weight [kg] divided by height [m] squared.
Confounders
Potential confounders such as age (continuous), sex, country (6 categories: Estonia, Germany,
Hungary, Italy, Spain, Sweden), maximum ISCED (International Standard Classification of
Education [36]) level of parents (three categories: low level (ISCED 0,1,2); medium (ISCED
3,4); high (ISCED 5,6)) [36], parental smoking (5 categories, only assessed at T3: current daily
smoker; current occasional smoker; ex-smoker; ex-smoker with missing pack years; never
smoker), family history of hypertension (yes vs. no; as reported for biological parents/siblings
at any of the three time points), BMI z-scores calculated based on Cole & Lobstein (2012) [37],
height, birth weight and pubertal stage (pubertal, pre-pubertal, no information available;
defined based on voice change in boys and first menstrual period in girls) were considered. To
account for individual variations in the whole blood FA content depending on the FA distribu-
tion in lipid classes of plasma, lipoproteins and red blood cells of whole blood [32], we included
weight percentage of total saturated (SFA) and total monounsaturated FA (MUFA) of total FA
as covariates. A binary variable indicating control versus intervention regions was used to
adjust for potential differences resulting from the intervention [29]. As indicator of dietary salt
intake we used the weekly frequency of processed food consumption which includes Ham-
burger, hot dog, kebab, wrap, falafel, salty snacks such as savory pastries and fritters as well as
cold cuts and ready to cookmeat products. Television and computer time calculated as average
screen time per week was also considered as a potential confounder.
Physical activity (PA) was measured objectively in a subset of children using the uniaxial
Actigraph accelerometer (Actigraph MTI, model GT1M,Manufacturing Technology Inc., Fort
Walton Beach, FL, USA) and the ActiTrainer which was the same technology as the Actigraph.
We used time spent in moderate-to-vigorous physical activity (MVPA) according to the cut-
points of Evenson et al. (2008) [38] including children with at least 3 accelerometer measure-
ment days and at least 360 minutes of valid time per day as indicator of PA in sensitivity
analyses.
Statistical analyses
Mixed-effectsmodels were used to assess the associations between the different FA measured
at baseline and BP z-scores over time. These models provide a flexible tool to model repeated
Fatty Acids and Blood Pressure in Children
PLOS ONE | DOI:10.1371/journal.pone.0165981 November 2, 2016 5 / 17
measurements data as they do not require individuals to be measured at the same ages and as
subjects with a varying number of repeated measurements can be considered under a missing
at random assumption[39]. They further allow for correlations among repeated measurements
taken from the same subject. In the present analysis, all children with a baseline and at least
one follow-up BP measurement were included (N = 1267; 1267 baselinemeasurements; 1069
T1 measurements and 667 T3 measurements). A variable indicating time since baseline was
constructed to assess how associations change over time (takes the values 0 for the baseline sur-
vey, approx. 2 years for the first follow-up and approx. 6 years for the second follow-up). The
model was built as follows:
BPi;j ¼ ðb0 þ ui;0Þ þ ðb1 þ ui;1Þ time since T0j þ b2T0 exposurei
þ b3T0 exposurei  time since T0i;j þ bcovarsT0 covariatesi
þ εi;j
BPi,j denotes the outcome value of individual imeasured at time j (i = 1,. . .NwhereN denotes the
number of study subjects; j = 0,1,2 denotes the surveywave), β0 denotes the intercept, ui,0 a ran-
dom subject-specific intercept, β1 indicates the yearly change in average BP levels since baseline,
ui,1 is a random subject-specific slope allowing BP to change differently in individuals over time,
β2 is the effect of the T0 exposure on the outcome at T0, β3 describes the change per year in the
effect of the FA exposure at baseline on BP over time and finally βcovars was used to indicate all
effect estimates of the covariates included in the different models (e.g. if age and sex were included
as covariates, βcovars would indicate the two effect estimates βage and βsex for age and sex). εi,j is the
error term for individual i at time j. An unstructured covariancematrix was selected for the ran-
dom effects, i.e. each variance/covariance could take the value that the data demand.
For all exposures and the two outcomes (SBP z-score, DBP z-score), a basic model adjusting
only for age (continuous), sex, height, country and intervention vs. control region (dummy var-
iable) was estimated in a first step. In a second step, the following covariates were added to the
basic model: maximum ISCED level of parents, parental smoking, family history of hyperten-
sion, BMI z-score, pubertal status, birth weight, weight percentage of the sum of SFA and of
MUFA of total FA, weekly frequency of processed food consumption and weekly hours of
screen time (fully adjusted model). Due to the significant interaction between EPA and weight
status, models were further estimated stratified by sex and stratified by BMI category (thin/nor-
mal weight vs. overweight/obese; categorization according to Cole & Lobstein (2012) [37]).
In the subgroup with available accelerometer data (N = 1035), the fully adjusted model was
additionally adjusted for minutes in MVPA.
All analyses were performed using SAS1 statistical software version 9.3 (SAS Institute, Inc.,
Cary, NC). All models were run using SAS Proc Mixed.
P values were not adjusted for multiple comparisons because of the explorative nature of
this study. A P value of 0.01 was used as the level of statistical significance to account at least
partially for multiple testing.
Results
The baseline characteristics of the study population are presented in Table 1. Of the girls,
20.7% and of the boys 20.2% were classified as pre-hypertensive or hypertensive. BP z-scores
were higher in girls than in boys. Weight percentages of PUFA were similar among BP catego-
ries. 42% of the children were overweight or obese with slightly more boys than girls being clas-
sified as obese. BMI z-scores were higher whereas birth weight was slightly lower in children
with normal BP compared to hypertensive children. Among the 220 children with a family
Fatty Acids and Blood Pressure in Children
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Table 1. Baseline characteristics of the study population by blood pressure category1 and sex.
All Normal BP Pre-hypertension Hypertension Girls Boys
Sex, n (%) Girls 1267 494 (79.3) 70 (11.2) 59 (9.5) 623 (49.2) 644 (50.8)
Boys 514 (79.8) 78 (12.1) 52 (8.1)
Age, years Mean (SD) 6.25 (1.7) 6.27 (1.7) 5.93 (1.9) 6.49 (2.0) 6.26 (1.7) 6.24 (1.8)
2-<6 years, n (%) 509 (40.2) 406 (79.8) 66 (13.0) 37 (7.3) 253 (49.7) 256 (50.3)
6-<10 years, n (%) 758 (59.8) 602 (79.4) 82 (10.8) 74 (9.8) 370 (48.8) 388 (51.2)
BP, Mean (SD) SBP (mmHg) 101.4 (9.60) 98.8 (7.57) 107.4 (7.88) 117.2 (9.43) 101.0 (9.52) 101.8 (9.67)
DBP (mmHg) 63.6 (6.52) 61.7 (5.21) 68.9 (4.44) 74.1 (5.58) 63.8 (6.46) 63.4 (6.58)
SBP, z-score 0.40 (0.80) 0.15 (0.60) 1.03 (0.54) 1.87 (0.64) 0.46 (0.82) 0.36 (0.78)
DBP, z-score 0.64 (0.59) 0.46 (0.45) 1.20 (0.38) 1.56 (0.57) 0.66 (0.59) 0.62 (0.59)
PUFA, Mean (SD), % wt/wt2 18:2n-6, LA 17.8 (1.96) 17.9 (1.94) 17.6 (1.94) 17.9 (2.17) 18.0 (1.99) 17.7 (1.93)
18:3n-6, GLA 0.23 (0.09) 0.23 (0.09) 0.22 (0.08) 0.23 (0.09) 0.22 (0.09) 0.23 (0.09)
20:3n-6, DGLA 1.23 (0.26) 1.23 (0.27) 1.20 (0.24) 1.22 (0.28) 1.20 (0.26) 1.25 (0.27)
20:4n-6, ARA 7.47 (1.31) 7.46 (1.30) 7.57 (1.29) 7.40 (1.40) 7.38 (1.34) 7.55 (1.27)
18:3n-3, ALA 0.20 (0.09) 0.20 (0.09) 0.19 (0.09) 0.21 (0.09) 0.20 (0.09) 0.20 (0.08)
20:5n-3, EPA 0.28 (0.12) 0.27 (0.12) 0.27 (0.11) 0.30 (0.13) 0.28 (0.13) 0.27 (0.11)
22:6n-3, DHA 1.23 (0.44) 1.23 (0.44) 1.23 (0.40) 1.24 (0.44) 1.21 (0.44) 1.26 (0.44)
SFA, Mean (SD), % wt/wt sum 44.4 (1.89) 44.4 (1.92) 44.5 (1.77) 44.3 (1.87) 44.4 (1.96) 44.5 (1.83)
MUFA, Mean (SD), % wt/wt sum 25.2 (2.35) 25.2 (2.32) 25.2 (2.49) 25.2 (2.48) 25.3 (2.42) 25.1 (2.29)
Family history of hyperten-
sion, n (%)
no 1047 (82.6) 848 (81.0) 117 (11.2) 82 (7.8) 517 (49.4) 530 (50.6)
yes 220 (17.4) 160 (72.7) 31 (14.1) 29 (13.2) 106 (48.2) 114 (51.8)
ISCED level, n (%) Level 0, 1, 2 148 (11.7) 117 (79.1) 17 (11.5) 14 (9.5) 69 (46.6) 79 (53.4)
Level 3, 4 664 (52.4) 541 (81.5) 70 (10.5) 53 (8.0) 320 (48.2) 344 (51.8)
Level 5, 6 455 (35.9) 350 (76.9) 61 (13.4) 44 (9.7) 234 (51.4) 221 (48.6)
Height, Mean (SD) cm 119.2 (12.5) 119.4 (11.8) 116.8 (13.8) 120.9 (15.5) 118.7 (12.1) 119.7 (12.7)
BMI, Mean (SD) kg/m2 17.9 (3.25) 17.6 (3.08) 18.0 (3.29) 20.2 (3.74) 17.7 (3.08) 18.0 (3.40)
BMI, Mean (SD)2 z-score 0.98 (1.30) 0.90 (1.29) 0.97 (1.34) 1.75 (1.15) 0.96 (1.23) 1.00 (1.38)
BMI category, n (%)3 Thin 76 (6.0) 64 (84.2) 10 (13.2) 2 (2.6) 31 (40.8) 45 (59.2)
Normal weight 659 (52.0) 551 (83.6) 73 (11.1) 35 (5.3) 330 (50.1) 329 (49.9)
Overweight 281 (22.2) 215 (76.5) 36 (12.8) 30 (10.7) 142 (50.5) 139 (49.5)
Obese 251 (19.8) 178 (70.9) 29 (11.6) 44 (17.5) 120 (47.8) 131 (52.2)
Birth weight, Mean (SD) g 3373 (545) 3376 (548) 3367 (571) 3352 (471) 3303 (532) 3440 (548)
Parental smoking, n (%)2 Never smoker 336 (26.5) 272 (81.0) 39 (11.6) 25 (7.4) 174 (51.8) 162 (48.2)
Current smoker 181 (14.3) 142 (78.5) 27 (14.9) 12 (6.6) 91 (50.3) 90 (49.7)
Ex-smoker 142 (11.2) 120 (84.5) 14 (9.9) 8 (5.6) 60 (42.3) 82 (57.7)
Missing information 608 (48.0) 474 (78) 68 (11.2) 66 (10.9) 298 (49.0) 310 (51.0)
Consumption frequency of
processed food, Mean (SD)
times per week 5.4 (4.9) 5.3 (4.9) 5.9 (5.5) 5.8 (4.4) 5.2 (4.6) 5.6 (5.3)
Time spent with audiovisual
media, Mean (SD)
hours per week 12.1 (7.9) 12.1 (8.0) 12.2 (7.5) 12.4 (6.8) 10.8 (6.5) 13.4 (8.9)
1National Institutes of Health 2005
2As only selected PUFA are shown, the sum of SFA, MUFA and PUFA does not sum up to 100%
3Cole & Lobstein 2012
ALA, alpha-linolenic acid; ARA, arachidonic acid; BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; DHA, docosahexaenoic acid;
DGLA, dihomo-gamma-linolenic acid; EPA, eicosapentaenoic acid; GLA, gamma-linolenic acid; ISCED, International Standard Classification of Education;
LA, linoleic acid; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SBP, systolic blood pressure; SD, standard deviation; SFA,
saturated fatty acids
doi:10.1371/journal.pone.0165981.t001
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history of hypertension, 27.3% were pre-hypertensive or hypertensive while this was true for
only 19.0% of the 1047 children without family history of hypertension. 21.5% of children
whose parents were current smokers were pre-hypertensive or hypertensive whereas this
applied to 18.0% of children with never or ex-smoker parents.
Table 2 shows the associations of the different PUFA with SBP and DBP z-scores at baseline,
after two years and after six years of follow-up. In the fully adjusted model, baseline ARA was
positively associated with subsequent SBP and DBP indicating that 1 unit increase of ARA was
associated with a 0.08 units higher SBP and a 0.07 units higher DBP z-score after 6 years.
Results stratified by BMI category revealed that associations differ by baseline BMI
(Table 3). The observedpositive association betweenARA and BP pointed to the same direc-
tion in all subgroups. In thin/normal weight children, inverse associations of baseline ALA and
EPA with SBP z-score at baseline and after 2 years of follow up and of baseline ALAwith subse-
quent DBP z-score were observed.Children classified as overweight/obese showed a positive
association of baseline EPA with DBP z-score at baseline. For instance, one unit increase of
Table 2. Associations of polyunsaturated fatty acids with systolic and diastolic blood pressure z-scores at baseline, after 2 years and after 6
years of follow-up estimated based on fully adjusted mixed-effects models1.
Fatty acid Time since baseline years SBP DBP
β P value β P value
18:2n-6, LA 0 -0.02 0.212 -0.02 0.024
2 -0.02 0.198 -0.02 0.086
6 -0.02 0.372 0.00 0.839
18:3n-6, GLA 0 -0.17 0.453 -0.16 0.324
2 -0.09 0.655 0.04 0.739
6 0.07 0.820 0.45 0.046
20:3n-6, DGLA 0 0.02 0.819 -0.06 0.346
2 0.04 0.638 0.01 0.875
6 0.08 0.521 0.15 0.071
20:4n-6, ARA 0 0.04 0.100 0.01 0.682
2 0.05 0.012 0.03 0.050
6 0.08* 0.002 0.07** 0.000
18:3n-3, ALA 0 -0.25 0.362 -0.01 0.971
2 -0.36 0.163 -0.18 0.338
6 -0.59 0.136 -0.53 0.059
20:5n-3, EPA 0 -0.26 0.158 0.11 0.382
2 -0.31 0.073 -0.07 0.568
6 -0.41 0.122 -0.42 0.019
22:6n-3, DHA 0 -0.11 0.048 -0.01 0.869
2 -0.10 0.064 -0.02 0.641
6 -0.06 0.385 -0.04 0.466
1Model, adjusted for age, sex, height, country and intervention vs. control region, maximum ISCED level of parents, parental smoking, family history of
hypertension, BMI z-score, pubertal status, birth weight, weight percentage of the sum of SFA and of MUFA of total FA, weekly frequency of processed food
consumption and weekly hours of screen time.
*P<0.01;
**P<0.001
ALA, alpha-linolenic acid; ARA, arachidonic acid; BMI, body mass index; DBP, diastolic blood pressure; DHA, docosahexaenoic acid; DGLA, dihomo-
gamma-linolenic acid; EPA, eicosapentaenoic acid; GLA, gamma-linolenic acid; ISCED, International Standard Classification of Education; LA, linoleic acid;
MUFA, monounsaturated fatty acids; SBP, systolic blood pressure; SFA, saturated fatty acids
doi:10.1371/journal.pone.0165981.t002
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baseline EPA was associated with 0.85 units lower SBP z-score at baseline in thin/normal
weight children but with 0.54 higher DBP z-score at baseline in overweight/obesechildren.
Table 4 shows the associations stratified by sex which confirms the positive association of
baseline ARA with subsequent DBP in boys though not reaching significance in girls
(p = 0.010). In boys, baseline GLA was positively associated with subsequent DBP indicating
that 1 unit increase in GLAwas associated with a 0.78 unit higher DBP z-score.
In the subgroup analyses with additional adjustment for MVPA the overall trends of associ-
ations remained unaltered (data not shown).
Discussion
In our large sample of European children, we observed that high blood levels of ARA are posi-
tively associated with subsequent SBP and DBP z-scores indicating a small detrimental effect of
high ARA on BP. ALA and EPA showed a beneficial effect on BP in the subgroup of thin/
Table 3. Associations of fatty acids with systolic and diastolic blood pressure z-scores at baseline, after two years and after six years of follow-
up stratified by BMI category1.
Fatty acid Time since baseline years SBP, thin / normal
weight n = 735
SBP, overweight /
obese n = 532
DBP, thin / normal
weight n = 735
DBP, overweight /
obese n = 532
β P value β P value β P value β P value
18:2n-6, LA 0 0.01 0.565 -0.04 0.082 0.00 0.921 -0.04 0.012
2 0.00 0.900 -0.03 0.166 0.01 0.671 -0.03 0.035
6 -0.01 0.537 -0.01 0.820 0.01 0.425 -0.01 0.521
18:3n-6, GLA 0 -0.70 0.018 0.31 0.392 -0.40 0.067 0.06 0.809
2 -0.58 0.028 0.36 0.241 -0.21 0.254 0.19 0.346
6 -0.36 0.413 0.48 0.338 0.17 0.589 0.44 0.182
20:3n-6, DGLA 0 -0.01 0.923 0.00 0.982 -0.15 0.080 0.00 0.973
2 0.01 0.928 0.03 0.837 -0.11 0.140 0.09 0.312
6 0.05 0.748 0.07 0.679 -0.04 0.742 0.26 0.036
20:4n-6, ARA 0 0.02 0.582 0.04 0.255 -0.01 0.788 0.01 0.673
2 0.03 0.197 0.05 0.112 0.01 0.478 0.03 0.159
6 0.07 0.043 0.08 0.079 0.05 0.045 0.08 0.015
18:3n-3, ALA 0 -1.13* 0.003 0.49 0.250 -0.68 0.018 0.48 0.118
2 -1.03* 0.004 0.17 0.686 -0.75* 0.004 0.20 0.496
6 -0.85 0.091 -0.48 0.442 -0.89 0.016 -0.38 0.374
20:5n-3, EPA 0 -0.85* 0.001 0.38 0.148 -0.29 0.089 0.54* 0.005
2 -0.71* 0.007 0.09 0.723 -0.36 0.024 0.23 0.208
6 -0.42 0.238 -0.50 0.198 -0.51 0.029 -0.40 0.179
22:6n-3, DHA 0 -0.19 0.011 -0.03 0.786 -0.04 0.392 0.04 0.525
2 -0.14 0.039 -0.05 0.559 -0.06 0.201 0.03 0.596
6 -0.05 0.580 -0.09 0.412 -0.09 0.166 0.01 0.889
1Model adjusted for age, sex, height, country, intervention vs. control region, maximum ISCED (International Standard Classification of Education) level of
parents, parental smoking, family history of hypertension, BMI z-score, pubertal status, birth weight, weight percentage of the sum of SFA and of MUFA of
total FA, weekly frequency of processed food consumption and weekly hours of screen time.
*P<0.01
ALA, alpha-linolenic acid; ARA, arachidonic acid; BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; DHA, docosahexaenoic acid;
DGLA, dihomo-gamma-linolenic acid; EPA, eicosapentaenoic acid; GLA, gamma-linolenic acid; ISCED, International Standard Classification of Education;
LA, linoleic acid; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SBP, systolic blood pressure; SFA, saturated fatty acids
doi:10.1371/journal.pone.0165981.t003
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normal weight children in contrast to the results of previous observational studies investigating
childhoodblood n-3 PUFA (EPA and/or DHA) and BP [24–26, 40]. However, in overweight/
obese children an unfavorable effect of EPA was observed.Thus, this study shows that already
in children the weight status seems to modify the inverse association of n-3 FA with BP.
n-6 PUFA
The adverse effect of high ARA on BP observed in our study confirms previous results in
adults [41, 42] which to our knowledge have not been shown in children before. In contrast,
in a Finnish cohort childhood serum cholesterylester levels of ARA were inversely associated
with the BP after 27 years of follow-up but fat intake in Finland has strongly changed over
time [26] and is probably different from our study population. Additionally, other factors
may play a more important role after this long time period. ARAmetabolites like prostaglan-
dins and 20-HETE have vasoconstrictive, and thus blood pressure increasing, effects [15–17].
Additionally, ARA is a reliable indicator for animal-derived foods because the key desaturase
steps in the conversion of LA to ARA, delta-6 desaturase (D6D) and delta-5 desaturase
Table 4. Associations of fatty acids with systolic and diastolic blood pressure z-scores at baseline, after two years and after six years of follow-
up stratified by sex1.
Fatty acid Time since baseline years SBP, girls n = 623 SBP, boys n = 644 DBP, girls n = 623 DBP, boys n = 644
β P value β P value β P value β P value
18:2n-6, LA 0 -0.01 0.750 -0.03 0.131 -0.02 0.281 -0.03 0.055
2 -0.01 0.516 -0.02 0.244 -0.02 0.212 -0.01 0.325
6 -0.02 0.336 -0.01 0.791 -0.02 0.299 0.01 0.390
18:3n-6, GLA 0 -0.29 0.410 0.04 0.903 -0.44 0.078 0.05 0.818
2 -0.28 0.373 0.19 0.472 -0.25 0.240 0.29 0.087
6 -0.25 0.619 0.51 0.244 0.14 0.687 0.78* 0.009
20:3n-6, DGLA 0 0.03 0.841 0.00 0.968 -0.09 0.338 -0.06 0.512
2 0.05 0.665 0.00 0.983 -0.01 0.911 0.01 0.912
6 0.10 0.553 0.02 0.918 0.15 0.206 0.15 0.204
20:4n-6, ARA 0 0.01 0.677 0.06 0.041 0.01 0.601 0.00 0.987
2 0.04 0.216 0.06 0.024 0.03 0.141 0.03 0.180
6 0.09 0.024 0.07 0.071 0.07 0.010 0.08* 0.007
18:3n-3, ALA 0 -0.53 0.105 -0.19 0.655 -0.43 0.065 0.05 0.882
2 -0.88 0.082 -0.21 0.733 -0.69 0.059 -0.40 0.336
6 0.03 0.841 0.00 0.968 -0.09 0.338 -0.06 0.512
20:5n-3, EPA 0 -0.42 0.048 0.01 0.975 -0.14 0.342 0.50 0.044
2 -0.36 0.066 -0.18 0.554 -0.29 0.054 0.29 0.180
6 -0.25 0.429 -0.56 0.169 -0.59 0.019 -0.14 0.626
22:6n-3, DHA 0 -0.11 0.217 -0.11 0.178 0.01 0.884 -0.04 0.498
2 -0.07 0.336 -0.10 0.142 -0.01 0.889 -0.04 0.402
6 -0.01 0.942 -0.10 0.280 -0.04 0.603 -0.05 0.459
1Model adjusted for age, height, country, intervention vs. control region, maximum ISCED (International Standard Classification of Education) level of
parents, parental smoking, family history of hypertension, BMI z-score, pubertal status, birth weight, weight percentage of the sum of SFA and of MUFA of
total FA, weekly frequency of processed food consumption and weekly hours of screen time.
*P<0.01
ALA, alpha-linolenic acid; ARA, arachidonic acid; BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; DHA, docosahexaenoic acid;
DGLA, dihomo-gamma-linolenic acid; EPA, eicosapentaenoic acid; GLA, gamma-linolenic acid; ISCED, International Standard Classification of Education;
LA, linoleic acid; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SBP, systolic blood pressure; SFA, saturated fatty acids
doi:10.1371/journal.pone.0165981.t004
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(D5D), are inhibited by high concentrations of the substrate [15]. Thus, high blood ARA
reflects a higher consumption of animal-derived foods with high intake of animal fats. Such a
dietary pattern has also been shown to be associated with elevated BP because of the corre-
sponding high sodium intake [43]. We observed the association of baseline ARA with BP
after 6 years of follow up. This may indicate that the adverse effects of the dietary pattern
may become stronger with increasing age as dietary patterns have been shown to track from
childhood to adolescence [44].
As observed in boys in our study, a positive association of GLA with BP was also found in
Chinese andWestern Alaskan Native adults [13, 45]. GLA is generated from LA by D6D and
can—after being elongated to DGLA—further be desaturated by D5D to ARA. As D6D activity
is higher and D5D activity is lower in male subjects [46, 47], the positive association in boys
may be explained by sex differences in desaturase activity.
n-3 PUFA
Our results indicate a protective role of ALA and EPA against hypertension in thin/normal
weight children whereas in overweight/obesechildren high EPA seemed to affect DBP unfa-
vourably. Beneficial effects of n-3 PUFA on BP have been shown in several intervention studies
investigating the effect of supplemental FA intake [48–50] and in observational studies investi-
gating dietary intake [8, 23, 51–53]. While observational studies investigating the association of
n-3 PUFA blood levels and BP showed beneficial effects in adults [11, 42], results in children
and adolescents were not consistent and indicated unfavorable effects [24, 25, 40]. In a Danish
cross-sectional study including 8–11 year old children, whole-bloodEPA was associated with a
2.7 mmHg higher DBP per weight% EPA in boys but not in girls [24]. Also in a large Finnish
study an unexpectedpositive association of childhood cholesterylester EPA with BP after 27
years was observed indicating a stronger association in men than in women [26]. We did not
observe sex-specific but a weight status-specific disparity in the n-3 PUFA-BP association in
our study indicating a protective role of n-3 PUFA only in thin/normal weight children. Thus,
the unfavorable effects of a high BMI and an altered n-3 PUFA status may have overlaid the
protective effects of n-3 PUFA on BP. In line with our results, in Alaskan Native adults an
inverse association of a marine food biomarker in blood and BP was observed in non-obese but
not in obese subjects. The interaction of weight status and the biomarker was only significant
for DBP but not for SBP [54]. In our analysis group, a high proportion of children (42%) were
overweight or obese. Already in children, BMI has a strong independent blood pressure
increasing effect [55, 56], and thus in our study sample obese children were more often hyper-
tensive than thin or normal weight children. Additionally, overweight and obese children enter
puberty usually earlier than thin or normal weight children [57, 58]. As BP increases with
puberty [59, 60] and early puberty has shown to be a risk factor for later high BP [57], this may
have also contributed to higher BP in overweight/obesechildren. Also, inflammatory cytokines
and adipocytokines from adipose tissue in overweight and obese subjects were shown to
increase blood pressure [61, 62] such that obesity-related effects on BP may have overlaid the
BP lowering effects of n-3 PUFA observed in thin/normal weight children.
Data on the influence of BMI on blood n-3 LC PUFA concentrations are inconsistent [40,
63] whereas lower estimated D5D activity has consistently been observed in obese subjects
compared to normal weight subjects indicating a less effective last desaturation step to ARA
and EPA, respectively [63, 64]. Therefore, obese children may synthesize less EPA from its pre-
cursor. However, in our study, EPA percentages were slightly higher in overweight/obese chil-
dren compared to thin/normal weight children (data not shown). This may have resulted from
a higher total energy intake and a dietary pattern with high consumption of animal-derived
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foods including fish with high n-3 LC PUFA as also ARA percentages were higher in the upper
BMI categories reflecting higher consumption of animal-derived fats as discussed before and as
shown for overweight/obese subjects in previous studies [65–67].
Higher dietary EPA intake may be required to achieve BP lowering effects, particularly
regarding DBP, as shown in a meta-analysis on the effects of fish oil or n-3 LC PUFA supple-
ments on BP [23]. As children and adolescents generally do not meet the recommended dietary
intake of n-3 LC PUFA [68], an increase of dietary EPA may beneficially influence BP.
According to a recent meta-analysis of prospective cohort studies in adult populations
higher circulating DHA levels may prevent from elevated blood pressure [69]. In agreement
with this, our data point to an inverse association of DHA with SBP in thin/normal weight chil-
dren at baseline though the effect estimate did not reach statistical significance. In contrast,
two smaller cross-sectional studies showed that whole-bloodDHA was positively associated
with DBP in 8–11 year old boys [40] and that erythrocyteDHA was positively related with SBP
in 17 year old adolescents [25].
In our analysis, we used "time since baseline" (instead of age) as the main time axis in order
to assess how associations between the FA exposures and BP change over time. However, when
using age as the main time axis instead, we found that the association betweenALA and SBP
decreases with age whereas associations betweenARA and DHA with BP increase with age.
Limitations and strengths
A limitation of our study is that the repeated blood pressure measurements were taken only on
a single occasion at each surveywave whereas confirmation of BP values on repeated visits or
even ambulatory 24-hour monitoring is recommended for the diagnosis of hypertension.
Therefore intra-individual variability which is well documented in children could not be con-
sidered and may have led to an overestimation of BP values [35, 70].
We adjusted only partially for multiple testing by choosing a significance level of 0.01 but
no formal multiple testing correctionwas performed.
As detailed dietary intake data was only available in a smaller subgroup and would not have
reliably reflected dietary salt intake, we used the intake frequency of processed foods as a proxy
for sodium intake because processed foods have shown to be the main source of salt [71].
The large analysis group of>1200 children from 6 European countries as well as the longi-
tudinal design and detailed phenotyping of the children are important strengths of our study.
In all countries standardized protocols for data assessment, measurements and biosampling
were applied at all surveywaves and adherence to protocols was verified by a central quality
control.
Conclusions
Our results suggest that ARA adversely affects BP already in children and may contribute to
the development of hypertension whereas n-3 PUFA exert BP lowering effects in thin and
normal weight children. In overweight and obese children the detrimental effects of
increased weight status may have overlaid the protective effects of n-3 fatty acids such that
an unfavorable relation of EPA and DBP became apparent in this subgroup. Higher EPA,
and especially higher DHA, combined with a healthier food pattern might be required to
lower BP in both, thin/normal weight and overweight/obese children. Health interventions
need to consider effect modification by weight status and should focus particularly on over-
weight and obese children who are more susceptible to elevated BP despite high n-3 PUFA
levels.
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